Polypeptide Multilayer Nanofilms in Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Polypeptide Multilayer Nanofilms in Drug Delivery
Investigators are exploiting the tremendous structural diversity of polypeptides and their biophysical properties to develop novel drug carriers. Peptide-based materials hold out much promise for tailor-made targeting, penetration, and release of contents in a host of biological microenvironments.


Pharmaceutical Technology


In conclusion, substantial progress has been made in the development of the PMN platform technology in the past few years. From multiple angles the prospects for commercializing the technology look good. The technology is promising for biomaterials development, and it has good potential to influence development of a variety of approaches to drug delivery. The technology could also be useful for development of multifunctional biomaterials. For instance, a variety of bioactive peptides could be used simultaneously to functionalize a PMN for different purposes, or various drugs could be encapsulated simultaneously for co-delivery. It is possible that other basic themes for technology development have yet to be identified. It is certain in any case that many variations on the known themes wait to be explored.

Donald T. Haynie, PhD , is vice-president of research and chief scientific officer at Artificial Cell Technologies, Inc., 5 Science Park at Yale, New Haven, CT 06511, tel. 1 203.772.3430,

References

1. A. Samad et al., "Liposomal Drug Delivery Systems: An Update Review," Curr. Drug Deliv. 4, 297–305 (2008).

2. C. Nastruzzi, Lipospheres in Drug Targets and Delivery: Approaches, Methods, and Applications (Taylor & Francis, London, 2007).

3. K. Kataoka et al., "Block Copolymer Micelles for Drug Delivery: Design, Characterization and Biological Significance," Adv. Drug Deliv. Rev. 47, 113–131 (2001).

4. A.S. Hoffman, "Hydrogels for Biomedical Applications," Adv. Drug Deliv. Rev. 54, 3–12 (2002).

5. M.J. Lawrence and G.D. Rees, "Microemulsion-based Media as Novel Drug Delivery Systems," Adv. Drug Deliv. Rev. 45, 89–121 (2000).

6. H.L. Crampton and E.E. Simanek, "Dendrimers and Drug Delivery Vehicles: Non-Covalent Interactions of Bioactive Compounds with Dendrimers," Polym. Int. 56, 489–496 (2007).

7. R. Challa et al., "Cyclodextrins in Drug Delivery: An Updated Review," AAPS Pharm. Sci. Tech. 6, E329–E357 (2005).

8. L. Liu et al., "Pectin in Controlled Drug Delivery—A Review," Cellulose 14,15–24(2007).

9. P.P. Constantinides et al., "Advances in the Use of Tocols as Drug Delivery Vehicles," Pharm. Res. 23, 243–255, (2006).

10. S. Svenson, ed., Polymeric Drug Delivery I: Particular Drug Carriers (American Chemical Society, Washington, DC, 2006).

11. C. Alexander, "Theme Issue: Biomedical Materials," J. Mater. Chem. 17, 3963–3964 (2007).

12. J.S. Temenoff and A.G. Mikos, Biomaterials: The Intersection of Biology and Materials Science (Englewood Cliffs, New Jersey: Prentice-Hall, 2008).

13. J.M. Anderson and M.S. Shive, "Biodegradation and Biocompatibility of PLA and PLGA Microspheres," Adv. Drug Deliv. Rev. 28, 5–24 (1997).

14. D.T. Haynie et al., "Polypeptide Multilayer Films," Biomacromolecules 6, 2895–2913 (2005).

15. T.M. Cooper et al., "Preparation of Polypeptide-Dye Multilayers by an Electrostatic Assembly Process," Mater. Res. Soc. Symp. Proc. 351, 239–244 (1994).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here